From Lab to Line: W&J Instrument Launches Scalable & Affordable Viscometer Series to Bridge R&D and Production

From Lab to Line: W&J Instrument Launches Scalable & Affordable Viscometer Series to Bridge R&D and Production

The new series gives manufacturers in food, energy, and petrochemicals a unified standard for quality, combining lab-grade precision with industrial-scale efficiency. CHANGZHOU, China, Nov. 3, 2025 /PRNewswire/ -- W&J Instrument, a viscometer...

NAVER D2SF-backed Nota AI Lists on KOSDAQ, Embarking on Global Expansion in AI Model Compression and Optimization

NAVER D2SF-backed Nota AI Lists on KOSDAQ, Embarking on Global Expansion in AI Model Compression and Optimization

Successfully listed on KOSDAQ with unique competitiveness for AI lightweighting and optimization technology Driving rapid annual revenue growth through collaborations with global leaders including NVIDIA, Samsung Electronics, and Qualcomm Focusing...

SAMURAI Paint Celebrates 28 Years of Excellence with the Launch of Its First-Ever Car Spray Paint Series

SAMURAI Paint Celebrates 28 Years of Excellence with the Launch of Its First-Ever Car Spray Paint Series

KUALA LUMPUR, Malaysia, Nov. 3, 2025 /PRNewswire/ -- SAMURAI Paint, the internationally trusted name in motorcycle spray paints, proudly celebrates its 28th anniversary with a major milestone — the launch of its first-ever car spray paint series....

Zeekr Group Announces October 2025 Delivery Update

Zeekr Group Announces October 2025 Delivery Update

HANGZHOU, China, Nov. 1, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced its delivery results for October 2025. In...

Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer

Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer

– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naive patients with differentiated thyroid cancer – TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Sunao Fujioka;...

Fox ESS and OSW Ink Strategic Partnership for 2GWh Energy Storage Projects at All Energy 2025

Fox ESS and OSW Ink Strategic Partnership for 2GWh Energy Storage Projects at All Energy 2025

MELBOURNE, Australia, Oct. 31, 2025 /PRNewswire/ -- Fox ESS, a leading provider of renewable energy solutions, has officially announced a strategic partnership with OSW, Australia's premier solar wholesaler and distributor. The two companies have...

Alternō's Sand Battery Enters Japan: Decarbonizing Industrial Heat and Supplying Clean Heat for Greenhouse Farming

Alternō's Sand Battery Enters Japan: Decarbonizing Industrial Heat and Supplying Clean Heat for Greenhouse Farming

TSUKUBA, Japan, Oct. 31, 2025 /PRNewswire/ -- Alternō , an Asia-based climate-tech company pioneering sand-based thermal battery systems, announced today the establishment of Alternō Japan GK in Tsukuba City, Ibaraki Prefecture. This marks a major...

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus...

WEKA Announces New NeuralMesh Architecture Built for NVIDIA BlueField-4

WEKA Announces New NeuralMesh Architecture Built for NVIDIA BlueField-4

Revolutionary Platform Design Marks Major Evolution in AI Infrastructure, Eliminating Traditional CPU Requirements While Delivering Breakthrough Performance Density, Linear Scalability and Exceptional Power Efficiency for Enterprise AI Factories...

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial hemorrhage occurred. Data suggest that LT3001 has the potential to provide significant clinical...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • menu
    menu